NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Sixteen life science companies throughout North Carolina have received just over $1 million in grants from a state program to support their development of new technologies and products.

A $76,527 Institutional Development Grant from the North Carolina Biotechnology Center earlier in 2017 has given Western North Carolina university scientists and students access to an important new research tool.

Durham-based Grid Therapeutics, an oncology-focused biotechnology company, has signed an exclusive license agreement with Duke University to develop the first human-derived antibody as a targeted immunotherapy for cancer. 

The North Carolina Biotechnology Center awarded 47 loans and grants totaling $3.6 million to universities, bioscience companies and other entities in the fourth quarter of its 2016-2017 fiscal year ending June 30.

Eighteen bioscience companies previously funded by NCBiotech loans raised more than $128 million in follow-on funding from other sources during the fourth quarter of 2016-17.

A $75,000 grant from the North Carolina Biotechnology Center is helping Duke University researchers develop a cervical cancer screening tool that women everywhere might be able to use on themselves.

Seqirus, the Holly Springs vaccine manufacturer, recently achieved another major milestone in its efforts to support the U.S. government’s pandemic preparedness efforts, showing it can now produce 150 million doses of a mammalian cell-derived flu vaccine in the first six months of pandemic declaration.

Piedmont Animal Health is one of Greensboro's shining life science stars with a successful stragegy of being fast to the market with innovative products that are mostly conceived in its own labs.

California-based Aerie Pharmaceuticals, a clinical-stage company developing new treatments for glaucoma and other eye diseases, is expanding its R&D operations in Durham as some of its drug candidates move closer to commercialization.

Chapel Hill-based Cempra, a publicly held pharmaceutical company developing treatments for infectious diseases, plans to merge with privately held Melinta Therapeutics, an antibiotics developer based in New Haven, Conn.

Pfizer, the global pharmaceutical giant, will expand its vaccine-manufacturing plant in Sanford with a $100 million investment in gene therapy that will add 40 jobs to its workforce.

Citing the Research Triangle region’s prevalence of top talent and nationally ranked research universities, New Jersey-based Lifestar Pharma has purchased a Durham building for a new R&D and manufacturing operation.

Scott Levitan starts a new job today, as president and CEO of The Research Foundation of NC.

Burlington-based LabCorp, the global life sciences company built on laboratory diagnostic testing, anounced plans to acquire Chiltern International, a privately held contract research organization (CRO) that has its North American headquarters in Wilmington, for about $1.2 billion.

BioFluidica, a Chapel Hill company developing a product using liquid biopsies for cancer detection, has raised $4.1 million in a private equity offering.